Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer

Background <p>ERBB2/HER2 is overexpressed or mutated in ~15% of gastric cancers due to amplification or mutation of the <i>ERBB2</i> locus. While the tumor cell-intrinsic consequences of ERBB2 overexpression are well understood, much less is known about its effects on the tumor microenvironment.</p> Methods <p>We have developed genetically engineered ectopic and orthotopic syngeneic models of organoid-based gastric cancer that have allowed…